Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
528 results:

  • 1. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
    Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
    J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Indoxyl sulfate contributes to colorectal cancer cell proliferation and increased egfr expression by activating AhR and Akt.
    Ichisaka Y; Yano S; Nishimura K; Niwa T; Shimizu H
    Biomed Res; 2024; 45(2):57-66. PubMed ID: 38556263
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
    Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
    Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [History and Perspective of Chemotherapy in Advanced Esophageal cancer].
    Shiraishi K; Kato K
    Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Integrative multi-omics characterization reveals sex differences in glioblastoma.
    Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
    Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. BCL-X
    Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
    Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Update on Targeted Therapy and Immunotherapy for Metastatic colorectal cancer.
    Underwood PW; Ruff SM; Pawlik TM
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334637
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The role of anti-egfr rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.
    Ciardiello D; Mauri G; Sartore-Bianchi A; Siena S; Zampino MG; Fazio N; Cervantes A
    Cancer Treat Rev; 2024 Mar; 124():102683. PubMed ID: 38237253
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A partial epithelial-mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction.
    Pastorino GA; Sheraj I; Huebner K; Ferrero G; Kunze P; Hartmann A; Hampel C; Husnugil HH; Maiuthed A; Gebhart F; Schlattmann F; Gulec Taskiran AE; Oral G; Palmisano R; Pardini B; Naccarati A; Erlenbach-Wuensch K; Banerjee S; Schneider-Stock R
    J Pathol; 2024 Mar; 262(3):347-361. PubMed ID: 38235615
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer.
    Jones VT; Graves-Deal R; Cao Z; Bogatcheva G; Ramirez MA; Harmych SJ; Higginbotham JN; Sharma V; Damalanka VC; Wahoski CC; Joshi N; Irudayam MJ; Roland JT; Ayers GD; Liu Q; Coffey RJ; Janetka JW; Singh B
    Cell Mol Life Sci; 2024 Jan; 81(1):28. PubMed ID: 38212428
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Targeted Mass Spectrometry Analyses of Somatic Mutations in colorectal cancer Specimens Using Differential Ion Mobility.
    Wu Z; Bonneil É; Belford M; Boeser C; Dunyach JJ; Thibault P
    J Proteome Res; 2024 Feb; 23(2):644-652. PubMed ID: 38153093
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
    Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
    Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Analysis of an Unselected Patient Cohort With Advanced colorectal Carcinoma from a Maximum Care Center.
    Zhang XW; Mohr J; Halama N; Koschny R
    Anticancer Res; 2023 Dec; 43(12):5589-5596. PubMed ID: 38030166
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic and predictive biomarkers for anti-egfr monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The efficacy and safety of anti-egfr target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials.
    Wang Y; Li X; Huang T; Wang D; He Y; Wei M; Chen Y; Zheng M; Shi Y; Zhang J
    World J Surg Oncol; 2023 Oct; 21(1):340. PubMed ID: 37880688
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. RIZ2 at the crossroad of the EGF/egfr signaling in colorectal cancer.
    Di Donato M; Di Zazzo E; Salvati A; Sorrentino C; Giurato G; Fiore D; Proto MC; Rienzo M; Casamassimi A; Gazzerro P; Bifulco M; Castoria G; Weisz A; Nassa G; Abbondanza C
    J Transl Med; 2023 Oct; 21(1):736. PubMed ID: 37853459
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.
    Kuol N; Godlewski J; Kmiec Z; Vogrin S; Fraser S; Apostolopoulos V; Nurgali K
    BMC Cancer; 2023 Oct; 23(1):971. PubMed ID: 37828429
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Claudin-2 protects against colitis-associated cancer by promoting colitis-associated mucosal healing.
    Ahmad R; Kumar B; Thapa I; Tamang RL; Yadav SK; Washington MK; Talmon GA; Yu AS; Bastola DK; Dhawan P; Singh AB
    J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 37815870
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
    Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
    Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing egfr mRNA in an m
    Chen LJ; Liu HY; Xiao ZY; Qiu T; Zhang D; Zhang LJ; Han FY; Chen GJ; Xu XM; Zhu JH; Ding YQ; Wang SY; Ye YP; Jiao HL
    Cell Death Dis; 2023 Sep; 14(9):581. PubMed ID: 37658049
    [TBL] [Abstract] [Full Text] [Related]  


    of 27.